Ardelyx Inc (ARDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $776.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Ardelyx Inc (ARDX) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Ardelyx reported EPS of $0.00, above the -$0.02 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ARDX's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
ARDX Earnings Call
The latest ARDX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, ARDX beat 23, missed 13 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $127.66M, up 15.7% from $110.33M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.00 | -$0.02 | -$0.06 - $0.02 | +100.00% | Beat | N/A | 8 | 0 up, 1 down | Nov 3, 2026 | $127.66M |
| Jun 30, 2026 | -$0.07 | -$0.05 | -$0.06 - -$0.03 | -40.00% | Miss | N/A | 7 | 0 up, 4 down | Aug 6, 2026 | $120.88M |
| Mar 31, 2026 | -$0.15 | -$0.14 | -$0.16 - -$0.11 | -7.14% | Miss | N/A | 7 | 1 up, 0 down | Apr 30, 2026 | $94.47M |
| Dec 31, 2025 | $0.00 | -$0.02 | N/A | +91.37% | Beat | -108.5% | 7 | 0 up, 1 down | Feb 19, 2026 | $125.22M |
| Sep 30, 2025 | $0.00 | -$0.07 | -$0.09 - -$0.01 | +94.29% | Beat | N/A | 7 | 3 up, 0 down | Oct 30, 2025 | $110.33M |
| Jun 30, 2025 | -$0.08 | -$0.14 | -$0.17 - -$0.11 | +42.86% | Beat | N/A | 6 | 0 up, 0 down | Aug 4, 2025 | $97.66M |
| Mar 31, 2025 | -$0.17 | -$0.07 | -$0.14 - -$0.04 | -142.86% | Miss | N/A | 4 | 2 up, 0 down | May 1, 2025 | $74.11M |
| Dec 31, 2024 | $0.02 | $0.00 | -$0.04 - $0.02 | N/A | N/A | N/A | 4 | 6 up, 0 down | Feb 20, 2025 | $116.13M |
| Sep 30, 2024 | $0.00 | -$0.05 | -$0.08 - -$0.01 | +93.20% | Beat | -111.3% | 10 | 1 up, 0 down | Oct 31, 2024 | $98.24M |
| Jun 30, 2024 | -$0.07 | -$0.11 | -$0.14 - -$0.06 | +36.36% | Beat | N/A | 10 | 2 up, 1 down | Aug 1, 2024 | $73.22M |
| Mar 31, 2024 | -$0.11 | -$0.16 | -$0.25 - -$0.12 | +31.25% | Beat | N/A | 10 | 0 up, 1 down | May 2, 2024 | $46.02M |
| Dec 31, 2023 | -$0.12 | -$0.09 | -$0.13 - -$0.04 | -33.33% | Miss | -300.0% | 9 | 1 up, 0 down | Feb 22, 2024 | $34.36M |
| Sep 30, 2023 | $0.03 | -$0.11 | -$0.15 - -$0.06 | +127.27% | Beat | N/A | 8 | 0 up, 0 down | Oct 31, 2023 | $56.39M |
| Jun 30, 2023 | -$0.08 | -$0.11 | -$0.12 - -$0.10 | +27.27% | Beat | N/A | 7 | 1 up, 0 down | Aug 2, 2023 | $22.33M |
| Mar 31, 2023 | -$0.13 | -$0.10 | -$0.12 - -$0.08 | -30.00% | Miss | N/A | 6 | 1 up, 0 down | May 3, 2023 | $11.37M |
| Dec 31, 2022 | $0.06 | -$0.02 | -$0.17 - $0.10 | +400.00% | Beat | N/A | 6 | 0 up, 0 down | Mar 2, 2023 | $44.18M |
| Sep 30, 2022 | -$0.14 | -$0.17 | -$0.19 - -$0.14 | +17.65% | Beat | N/A | 7 | 1 up, 0 down | Nov 3, 2022 | $4.99M |
| Jun 30, 2022 | -$0.19 | -$0.20 | -$0.21 - -$0.17 | +5.00% | Beat | N/A | 7 | 0 up, 0 down | Aug 4, 2022 | $2.53M |
| Mar 31, 2022 | -$0.21 | -$0.23 | -$0.27 - -$0.18 | +8.70% | Beat | N/A | 7 | 0 up, 0 down | May 5, 2022 | $468000 |
| Dec 31, 2021 | -$0.31 | -$0.30 | -$0.50 - -$0.18 | -3.33% | Miss | N/A | 6 | 0 up, 0 down | Feb 28, 2022 | $1.03M |
| Sep 30, 2021 | -$0.42 | -$0.35 | -$0.48 - -$0.25 | -20.00% | Miss | N/A | 7 | N/A | Nov 12, 2021 | $1.17M |
| Jun 30, 2021 | -$0.45 | -$0.37 | -$0.40 - -$0.35 | -21.62% | Miss | N/A | 7 | N/A | Aug 13, 2021 | $1.31M |
| Mar 31, 2021 | -$0.34 | -$0.34 | -$0.38 - -$0.30 | 0.00% | In line | N/A | 7 | N/A | May 6, 2021 | $6.58M |
| Dec 31, 2020 | -$0.32 | -$0.26 | -$0.28 - -$0.24 | -23.08% | Miss | N/A | 6 | N/A | Mar 8, 2021 | $1.81M |
| Sep 30, 2020 | -$0.20 | -$0.30 | -$0.31 - -$0.26 | +33.33% | Beat | N/A | 6 | N/A | Nov 5, 2020 | $2.71M |
| Jun 30, 2020 | -$0.28 | -$0.25 | -$0.29 - -$0.22 | -12.00% | Miss | N/A | 6 | N/A | Aug 6, 2020 | $1.84M |
| Mar 31, 2020 | -$0.25 | -$0.25 | -$0.31 - -$0.22 | 0.00% | In line | N/A | 6 | N/A | May 7, 2020 | $1.21M |
| Dec 31, 2019 | -$0.27 | -$0.33 | -$0.37 - -$0.30 | +18.18% | Beat | N/A | 6 | N/A | Mar 6, 2020 | $2.23M |
| Sep 30, 2019 | -$0.37 | -$0.37 | -$0.40 - -$0.32 | 0.00% | In line | N/A | 5 | N/A | Nov 6, 2019 | $3.01M |
| Jun 30, 2019 | -$0.41 | -$0.38 | -$0.40 - -$0.37 | -7.89% | Miss | N/A | 4 | N/A | Aug 9, 2019 | $36000 |
| Mar 31, 2019 | -$0.42 | -$0.39 | -$0.44 - -$0.35 | -7.69% | Miss | N/A | 5 | N/A | May 7, 2019 | N/A |
| Dec 31, 2018 | -$0.45 | -$0.41 | -$0.47 - -$0.36 | -9.76% | Miss | -314.3% | 4 | N/A | Mar 6, 2019 | $55000 |
| Sep 30, 2018 | -$0.39 | -$0.43 | -$0.47 - -$0.37 | +9.30% | Beat | N/A | 5 | N/A | Nov 7, 2018 | $172000 |
| Jun 30, 2018 | -$0.42 | -$0.44 | -$0.47 - -$0.38 | +4.55% | Beat | N/A | 6 | N/A | Aug 7, 2018 | $60000 |
| Mar 31, 2018 | -$0.36 | -$0.46 | -$0.50 - -$0.39 | +21.74% | Beat | N/A | 5 | N/A | May 8, 2018 | $2.32M |
| Dec 31, 2017 | $0.21 | -$0.41 | -$0.53 - -$0.10 | +151.22% | Beat | N/A | 7 | N/A | Mar 14, 2018 | $42.00M |
| Sep 30, 2017 | -$0.44 | -$0.54 | -$0.56 - -$0.48 | +18.52% | Beat | N/A | 7 | N/A | Nov 7, 2017 | N/A |
| Jun 30, 2017 | -$0.54 | -$0.65 | -$0.67 - -$0.62 | +16.92% | Beat | N/A | 6 | N/A | Aug 9, 2017 | N/A |
| Mar 31, 2017 | -$0.59 | -$0.67 | N/A | +11.94% | Beat | N/A | N/A | N/A | May 5, 2017 | N/A |
| Dec 31, 2016 | -$0.66 | -$0.72 | N/A | +8.33% | Beat | N/A | N/A | N/A | Feb 17, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.26, after -$0.16 the year before. It was -$2.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.26 | N/A |
| Dec 31, 2024 | -$0.16 | N/A |
| Dec 31, 2023 | -$0.30 | N/A |
| Dec 31, 2022 | -$0.48 | N/A |
| Dec 31, 2021 | -$1.52 | N/A |
| Dec 31, 2020 | -$1.05 | N/A |
| Dec 31, 2019 | -$1.47 | N/A |
| Dec 31, 2018 | -$1.62 | N/A |
| Dec 31, 2017 | -$1.36 | N/A |
| Dec 31, 2016 | -$2.84 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,844 | 15 | |
| 2026Q2 | Jun 30, 2026 | 4,798 | 13 | |
| 2026Q1 | Mar 31, 2026 | 8,056 | 15 | |
| 2025Q4 | Dec 31, 2025 | 8,604 | 17 | |
| 2025Q3 | Sep 30, 2025 | 6,548 | 15 | |
| 2025Q2 | Jun 30, 2025 | 7,122 | 16 | |
| 2025Q1 | Mar 31, 2025 | 6,148 | 13 | |
| 2024Q4 | Dec 31, 2024 | 7,073 | 14 |
2026Q3 Earnings Call
Opening remarks
Lisa Caperelli SVP, Investor Relations and Corporate Communications Thank you, Paul. Good afternoon, and welcome to our third quarter 2026 financial results and business update call. Earlier today, we issued our earnings release, which can be found in the Investors section of our website at ardelyx.com. Slides that accompany today's call can also be found on our website. On today's call, I am joined by Mike Raab, President and CEO of Ardelyx, and Sue Hohenleitner, our Chief Financial Officer. Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties that may cause our actual results to differ materially from those expressed or implied, including those described in our annual report on Form 10-K, our quarterly report on Form 10-Q, which was filed today, and from time to time in our other documents filed with the SEC. These forward-looking statements speak only as of today's date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our views change. I will now pass the call over to Mike. Mike?
Michael Raab President and CEO Thank you, Lisa. Good afternoon, everyone, and thank you for joining us today. Ardelyx is a company focused on developing and commercializing innovative medicines. Today, with IBSRELA and XPHOZAH, we have two first-in-class medicines that in the third quarter generated over $125 million in revenue, up 19% from a year ago. With a strengthened financial position and a robust patent portfolio, our products are well positioned for significant long-term growth. Our focus is now to leverage that foundation and build a pipeline to create long-term value. Our third quarter performance bolsters our confidence as we focus on executing on our priorities: accelerating the growth of IBSRELA, maintaining XPHOZAH's momentum, building and expanding our pipeline, and delivering strong financial results. Starting with IBSRELA. In Q3, IBSRELA generated revenue of $96.3 million, representing 23% year-over-year growth. HCP confidence in IBSRELA remains high, with demand reaching all-time highs as the number of total writers, total prescriptions, and market share continues to grow. This growth supports our full-year guidance and reinforces our long-term view of achieving $1 billion in annual revenue. Critical to that is our ongoing work to thoughtfully eliminate the payer friction HCPs and patients experience when first starting IBSRELA. In our efforts to alleviate some of this friction in the third quarter, we began to see progress that gave us confidence these initiatives are beginning to take hold. As we've noticed in the past, IBSRELA is a promotionally sensitive brand.
Frequently Asked Questions About ARDX
Did ARDX beat earnings estimates last quarter?
Yes. Ardelyx reported EPS of $0.00 for the quarter ended Sep 30, 2026, above the -$0.02 estimate, a 100.00% surprise.
What EPS do analysts expect from ARDX next quarter?
The consensus EPS estimate for Ardelyx for the quarter ending Dec 31, 2026 is $0.04 from 13 analysts, with estimates from $0.02 to $0.06.
How often does ARDX beat earnings estimates?
Ardelyx beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +28.96%.
ARDX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts